Back to search results

Pilot Study: Mailing Buprenorphine for Opioid Use Disorder

This pilot study is looking at a new way to help people with opioid use disorder (OUD) stay in treatment. It's testing if mailing buprenorphine (a medication used to treat OUD) directly to your home can help overcome problems like not having transportation or difficulty getting to a pharmacy. The study aims to enroll 20 English-speaking adults, aged 18 or older, who have OUD and are starting buprenorphine while in the hospital. You must be discharging to a South Carolina address with a stable mailbox and have access to a phone or computer. The main goals are to see if mailing buprenorphine is practical (successful delivery) and if it helps people stay in treatment for up to 6 months. The study's status is currently unclear.

Study design
This is a single-center pilot study with 20 participants. It is an interventional study, meaning participants will receive a specific intervention.
What's involved
Participants will be enrolled in a program that mails monthly buprenorphine refills directly to their homes for up to 6 months.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed from enrollment to the end of the study at 6 months to assess successful receipt and retention in treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07421102

Pilot of Mailing Buprenorphine

Recruiting
EARLY_PHASE1Ages 18+Interventional
Medical University of South Carolina
~20 participants
Updated 2026-07-30 on ClinicalTrials.gov
What's tested:strategy of mailing buprenorphine

At a glance

Recruiting sites
1 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Feasibility (successful receipt)
Measured over From enrollment to the end of the study at 6 months
+2 more outcomes measured

Conditions

Opioid Use Disorder

Explore related trials

Opioid Use Disorder

Where it's being run

2 sites across 1 states
South Carolina2

Study leadership

  • Allison Smith, MD · PRINCIPAL_INVESTIGATOR · Medical University of South Carolina

Who to contact

Primary Investigator, MD
[email protected]
843-792-0686
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age ≥ 18
English-speaking
Diagnosed with OUD and initiated on buprenorphine during hospitalization
Discharging to a South Carolina address with a stable mailbox
Access to phone or computer

Exclusion

Active psychosis or suicidal ideation
Severe medical or neurocognitive impairment
Pending incarceration

What this trial measures

  • Feasibility (successful receipt)From enrollment to the end of the study at 6 months

    Successful delivery and receipt of medication defined by self-report and phone/text/video confirmation to receive code

  • Successful receiptFrom enrollment to the end of study at 6 months.

    Feasibility is defined by the successful receipt of the buprenorphine prescriptions in the mail by the intended participants. Successful receipt defined by self-report and phone/text/video confirmation from participant. Delivery failure is defined as delay in receipt of medication by \>48 hours by the mail delivery service.

  • Retention in treatmenttime of study enrollment to end of study at 6 months

    Preliminary effectiveness of mailing buprenorphine will be measured by retention in treatment. This is defined by the proportion of participants retained in buprenorphine treatment at 1,3, and 6 months after discharge.